An observational study in Encephalitis, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2022-06-30.
Sponsored by Bristol-Myers Squibb · Observational
A case series analysis of encephalitis events reported to the Sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.
284 studies on the registry are indexed under Encephalitis; 56 are open to participants now.
This study's enrollment of 486 is above the median of 205 across 94 observational studies indexed under Encephalitis.
Browse Encephalitis studies →Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 118 are open to participants now.
Of its 435 completed or terminated interventional studies of FDA-regulated products, 227 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Case series reported to the sponsor from various health care facilities
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Case series reported to the sponsor from various health care facilities
Biological: Nivolumab
Specified dose on specified days
Outcomes of Encephalitis
Time since onset of immune-mediated encephalitis to the date of outcome assessment (days) and outcomes defined as: resolved, resolving, death, physical disability (specified), cognitive disability (specified)
Time frame: 1 year
Risk factors of Encephalitis
Potential risk factors include but are not limited to medical history including event associated signs/symptoms, and data from brain imaging diffusion, results from lumbar puncture analyses, results from serum sample analyses and results from neurologic examinations
Time frame: 1 year
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.